AUTHORS
Saurabh Dahiya, MD, FACP, Matthew L. Ulrickson, MD2, Jean Yared, MD3, Patrick M Reagan, MD4, Timothy J Voorhees, MD,MSc5, Andre Goy, MD6, Cameron J. Turtle, MBBS, PhD7, Lizamarie Bachier-Rodriguez, MD8, Ran Reshef, MD, MSc9, Marie Jose Kersten, MD10, Prof. Dr. Max Topp, MD11, Robin Sanderson, PhD, FRCPath12, Loretta Nastoupil, MD13, Scott Jung14, Jinghui Dong15, Joshua Winters16, Rhine Shen, PhD17, Justyna Kanska, PhD18, Myrna Nahas, MD19, Sairah Ahmed, MD20
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States
2 Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
3 University of Maryland School of Medicine, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
4 University of Rochester School of Medicine, Rochester, New York, United States
5 The Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, United States
6 John Theurer Cancer Center, Hackensack, New Jersey, United States
7 Royal North Shore Hospital, St. Leonards, NSW, Australia; University of Sydney, Camperdown, NSW, Camperdown, NSW, Australia
8 Blood and Marrow Transplant Group of Georgia and Northside Hospital, Atlanta, Georgia, United States
9 Columbia University Irving Medical Center, New York, New York, United States
10 Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
11 Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
12 King's College Hospital, London, England, United Kingdom
13 CommonSpirit Oncology Mercy, Durango, Colorado, United States
14 Kite, a Gilead Company, Santa Monica, California, United States
15 Kite, a Gilead Company, Santa Monica, California, United States
16 Kite, a Gilead Company, Santa Monica, California, United States
17 Kite, a Gilead Company, Santa Monica, California, United States
18 Kite, a Gilead Company, Santa Monica, California, United States
19 Kite, a Gilead Company, Santa Monica, California, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: An unmet need exists for treatment strategies that address resistance to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (Plaks, et al. Blood. 2021). KITE-753 is an investigational CAR T-cell therapy with a unique bicistronic design to engage both CD19 and CD20, synergistic CD28/4-1BB co-stimulation to enhance T-cell function, and a rapid manufacturing process that preserves naive and memory T cells. In initial analyses from Phase 1 of the PALISADES-1 open-label, multicenter trial (NCT04989803) of KITE-753 in pts with R/R B-cell lymphoma, KITE-753 showed promising efficacy and a favorable safety profile (Dahiya, et al. HemaSphere. 2026). Here, we report longer follow-up results to evaluate response durability. Translational correlative analyses, including product phenotyping and immune cell recovery, as well as molecular disease assessments will also be presented.
Methods: Adults with B-cell lymphoma R/R after ≥2 lines of therapy or with second-line primary refractory large B-cell lymphoma (LBCL) were eligible for enrollment in dose escalation (Phase 1a) and expansion (LBCL only; Phase 1b) cohorts. After lymphodepletion, pts received KITE-753 at 1 of 3 dose levels (DL; 0.3×105, 1×105, or 2×105 CAR T cells/kg in DL1, 2, or 3, respectively). The primary endpoints for Phase 1a and 1b were incidence of dose-limiting toxicities (DLTs) and investigator-assessed objective response rate (ORR; per Lugano), respectively. To contextualize findings, select outcomes were descriptively compared with those observed with the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) from the ZUMA-1 trial.
Results: As of 6/19/2026, 34 pts received KITE-753 (3 in DL1, 8 in DL2, 23 in DL3). Median follow-up in all pts was 13.9 months (range, 6.4-31.5). Median age was 60 years (range, 25-83); 24% of pts were ≥75 years. A total of 76% of pts had Stage III/IV disease and 50% had elevated pretreatment lactate dehydrogenase. Nine pts (26%) were primary refractory (only 1 prior line of therapy); 16 (47%) had received ≥2 prior lines and were primary refractory to first-line therapy. Ten pts (29%) had received prior anti-CD19 CAR T-cell therapy.
No DLTs occurred in dose escalation. Grade ≥3 adverse events occurred in 85% of pts (91% in DL3). Five pts (15%) had Grade ≥3 infections. There were 6 deaths across DLs, 4 due to disease progression and 2 due to infections unrelated to KITE-753 per the investigator. Grade 1/2 cytokine release syndrome (CRS) occurred in 50% of pts (61% in DL3); 1 pt had Grade 3 CRS (DL2). No Grade ≥4 CRS occurred. Median time to CRS onset was 6 days (range, 3-11); median duration was 6 days (range, 2-8). Grade 1/2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 21% of pts (22% in DL3); no Grade ≥3 ICANS occurred. Median time to ICANS onset was 10 days (range, 8-14); median duration was 2 days (range, 2-11). B-cell recovery, a potential indicator of reduced infection risk, was assessed; among CAR-naive pts in DL3 6 months after CAR T-cell infusion, 75% of evaluable pts had detectable B cells after KITE-753 versus 23% of pts who received axi-cel in ZUMA-1 (Cohorts 1+2).
The ORR was 89% and the complete response (CR) rate was 78% in CAR-naive pts in DL3 (n=18); 72% had achieved and maintained CR at the 6-month assessment. The CR rate was 78% in pts with baseline tumor CD19 H-scores ≤50 (n=9) and 86% in those with H-scores >50 (n=7); 67% and 86%, respectively, maintained CR at 6 months. Median duration of response, duration of CR, and progression-free survival were not reached in CAR-naive pts in DL3.
Conclusions: In CAR-naive pts at DL3, KITE-753 continued to demonstrate high CR rates, regardless of tumor CD19 expression, with response durability established with longer follow-up. At DL3, no high-grade CRS or ICANS were observed with KITE-753. Collectively, the favorable efficacy and safety profile of KITE-753 may reflect its dual-targeting design and rapid manufacturing process that preserves CAR T-cell fitness, as well as optimized dosing that mitigates toxicity and improves B-cell recovery. Based on these promising results, KITE-753 is currently being evaluated in Phase 2 of PALISADES-1 (R/R LBCL) and in the Phase 3 PALISADES-2 trial (NCT07479797) versus axi-cel in CAR-naive pts with primary refractory or early relapsed LBCL.
DISCLOSURES
Saurabh Dahiya, MD, FACP: Johnson and Johnson (Jansen Pharmaceuticals) - Honoraria; Kyverna Therapeutics - Research Funding; Kite, a Gilead Company - Research Funding; Novartis - Research Funding; Kite, a Gilead Company - Consultancy (Includes expert testimony); Kyverna Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Johnson and Johnson (Jansen Pharmaceuticals) - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony)